Kinnate Biopharma Financials

Kinnate Biopharma Stock Summary

Kinnate Biopharma competes with ACELYRIN, INC, Windtree Therapeutics, Palisade Bio, Century Therapeutics, and Passage Bio. Kinnate Biopharma Inc., a biopharmaceutical company, focuses on the discovery and development of small molecule kinase inhibitors to treat genomically defined cancers in the United States. Kinnate Biopharma Inc. is a former subsidiary of Fount Therapeutics, LLC. Kinnate Biopharma operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 82 people.

Kinnate Biopharma Key Financial Ratios

Kinnate Financial Ratios Relationships

Comparative valuation techniques use various fundamental indicators to help in determining Kinnate Biopharma's current stock value. Our valuation model uses many indicators to compare Kinnate Biopharma value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Kinnate Biopharma competition to find correlations between indicators driving Kinnate Biopharma's intrinsic value. More Info.Kinnate Biopharma is rated below average in return on equity category among its peers. It is rated below average in return on asset category among its peers . Comparative valuation analysis is a catch-all technique that is used if you cannot value Kinnate Biopharma by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.

Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. You can also try the Aroon Oscillator module to analyze current equity momentum using Aroon Oscillator and other momentum ratios.

If you are still planning to invest in Kinnate Biopharma check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Kinnate Biopharma's history and understand the potential risks before investing.